Exploratory study of plasma total homocysteine and its relationship to short-term outcome in acute ischaemic stroke in Nigerians by Okubadejo, Njideka U et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Neurology
Open Access Research article
Exploratory study of plasma total homocysteine and its relationship 
to short-term outcome in acute ischaemic stroke in Nigerians
Njideka U Okubadejo*1, Olajumoke O Oladipo2, Adekunle A Adeyomoye3, 
Gbolahan O Awosanya3 and Mustapha A Danesi1
Address: 1Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria, 2Department of Chemical Pathology, College of 
Medicine, University of Lagos, Lagos, Nigeria and 3Department of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, 
University of Lagos, Lagos, Nigeria
Email: Njideka U Okubadejo* - njide_okubadejo@yahoo.com; Olajumoke O Oladipo - jumsoladipo@yahoo.ca; 
Adekunle A Adeyomoye - kunleadeyomoye@yahoo.com; Gbolahan O Awosanya - gog_awosanya@yahoo.com; 
Mustapha A Danesi - mustaphadanesi@yahoo.com
* Corresponding author    
Abstract
Background: Hyperhomocysteinemia is a potentially modifiable risk factor for stroke, and may
have a negative impact on the course of ischaemic stroke. The role of hyperhomocysteinemia as it
relates to stroke in Africans is still uncertain. The objective of this study was to determine the
prevalence and short-term impact of hyperhomocysteinemia in Nigerians with acute ischaemic
stroke. We hypothesized that Hcy levels are significantly higher than in normal controls, worsen
stroke severity, and increase short-term case fatality rates following acute ischaemic stroke.
Methods: The study employed both a case-control and prospective follow-up design to study
hospitalized adults with first – ever acute ischaemic stroke presenting within 48 hours of onset.
Clinical histories, neurological evaluation (including National Institutes of Health Stroke Scale
(NIHSS) scores on admission) were documented. Total plasma Hcy was determined on fasting
samples drawn from controls and stroke cases (within 24 hours of hospitalization). Outcome at 4
weeks was assessed in stroke patients using the Glasgow Outcome Scale (GOS).
Results: We evaluated 155 persons (69 acute ischaemic stroke and 86 healthy controls). The mean
age ± SD of the cases was 58.8 ± 9.8 years, comparable to that of controls which was 58.3 ± 9.9
years (T = 0.32; P = 0.75). The mean duration of stroke (SD) prior to hospitalization was 43.5 ±
38.8 hours, and mean admission NIHSS score was 10.1 ± 7.7. Total fasting Hcy in stroke patients
was 10.2 ± 4.6 umol/L and did not differ significantly from controls (10.1 ± 3.6 umol/L; P = 0.88).
Hyperhomocysteinemia, defined by plasma Hcy levels > 90th percentile of controls (>14.2 umol/L
in women and >14.6 umol/L in men), was present in 7 (10.1%) stroke cases and 11 (12.8%) controls
(odds ratio 0.86, 95% confidence interval 0.31 – 2.39; P > 0.05). In multiple regression analysis
admission NIHSS score (but not plasma Hcy) was a significant determinant of 4 week outcome
measured by GOS score (P < 0.0001).
Conclusion: This exploratory study found that homocysteine levels are not significantly elevated
in Nigerians with acute ischaemic stroke, and admission Hcy level is not a determinant of short-
term (4 week) stroke outcome.
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Background
Stroke prevention is a key component of any public health
strategy aimed at reducing the rising burden of cardiovas-
cular diseases in low and middle income countries [1].
Several risk factors for stroke have been identified and are
the target of both primary and secondary preventive strat-
egies [2-4]. It has however become increasingly apparent
that apart from the traditional risk factors associated with
stroke, several newer independent risk markers that are
promising targets for modification, such as hyperhomo-
cysteinemia, may contribute substantially to the risk of
stroke.
Homocysteine (Hcy) is a sulphydryl-containing amino
acid derived from the metabolic demethylation of the die-
tary essential amino acid methionine by the liver and
other proliferating cells [5]. Hyperhomocysteinemia may
be genetic (due to cystathione β-synthase or methylenetet-
rahydrofolate reductase (MTHFR) mutations) or acquired
(dietary, renal impairment, drugs, and co-morbid ill-
nesses such as leukemia) [5,6]. The evidence for an asso-
ciation between hyperhomocysteinemia and
atherosclerotic disease has been present for over 30 years,
but has only more recently gained focus [7,8]. Hyperho-
mocysteinemia may promote oxidative injury to the vas-
cular bed with proliferation of vascular smooth muscle,
altered endothelial function, and enhanced thrombo-
genicity [9-11]. Emerging evidence from epidemiologic
studies supports a strong, dose-dependent, positive asso-
ciation between plasma Hcy level and the risk of cardio-
vascular diseases including stroke. Recent prospective and
retrospective studies have shown that high and moder-
ately elevated Hcy levels are potentially modifiable risk
factors for stroke in all age groups, independent of the
effect of smoking, cholesterol and blood pressure [12-18].
Additionally, increased levels of Hcy in blood seem to
have a negative impact on the course of ischaemic stroke,
significantly increasing the risk of poor recovery [19]. The
role of hyperhomocysteinemia as it relates to stroke in
Africans is still uncertain. The objective of this study was
thus to determine the prevalence of hyperhomocysteine-
mia in Nigerians with acute ischaemic stroke, and the
impact of hyperhomocysteinemia on short-term stroke
outcome. We hypothesized that Hcy levels in acute ischae-
mic stroke are significantly higher than in normal per-
sons, that Hcy levels are related to stroke severity, and
hyperhomocysteinemia increases the short-term case
fatality rates following ischaemic stroke in Nigerians.
Methods
Approval of the study protocol was obtained from the
Health Research and Ethics Committee of the Lagos Uni-
versity Teaching Hospital (LUTH), Lagos, Nigeria. The
study protocol encompassed two aspects. The first was a
case-control design to compare the levels of Hcy in per-
sons on admission for acute ischaemic stroke with age-
and sex-matched matched healthy controls. The second
design was a prospective 4-week follow up study of the
same cohort of stroke cases to determine the relationship
of admission Hcy levels to short-term stroke outcome.
We recruited all consecutive first – ever acute ischaemic
stroke patients presenting within 48 hours of onset of
focal neurological deficit and aged > 15 years. Informed
consent was obtained from all stroke cases or their prox-
ies. All the potential participants consented to participate
in the study, giving a zero non-response rate. Brain com-
puterized tomography (CT) scans were conducted to
exclude hemorrhagic stroke and other intracranial struc-
tural causes of focal neurological deficits. All CT scans
were reviewed by the study consultant radiologists to con-
firm the diagnosis of ischaemic stroke. In a few instances
where CT scan was not done, ischaemic stroke was diag-
nosed in cases that fulfilled both the World Health Organ-
ization [20] and Siriraj stroke score criteria [21] for
ischaemic stroke. The control group comprised of healthy
volunteers (including spouses of stroke cases and civil
servants) matched for age (± 2 years) and gender to con-
trols.
In each instance, the clinical history, cardiovascular and
neurological examination, and evaluation of stroke status
using the National Institutes of Health Stroke Scale
(NIHSS) [22] were documented. Patients with NIHSS
score > 13 were classified as severe stroke, while a score ≤
13 was regarded as mild stroke. Follow-up evaluations
were conducted at 4 weeks post-stroke onset. The evalua-
tions were conducted in hospital in all instances. This was
enabled by the operational unit protocol for stroke care at
our institution which includes 4 week hospitalization
period in all persons suffering a stroke. Outcome at 4
weeks was assessed on the Glasgow Outcome Scale [23]
with a score of 1 indicating good recovery, 2 – moderate
disability, 3 – severe disability, 4 – vegetative survival, and
5 – death.
Homocysteine assay
Total plasma Hcy was determined on fasting (after 12
hours) samples drawn within 24 hours of hospitalization
(within 72 hours of stroke onset in all instances, with a
range of 20 – 72 hours). Control samples were also col-
lected after a 12 hour fast. 5 ml of venous blood was col-
lected from each subject into EDTA tubes, transported to
the laboratory immediately, and separated within 1 hour
of collection. Plasma was stored at minus 20°C until
batched analysis after every 20 samples. Total L – Hcy was
assayed by the fluorescence polarization immunoassay
(FPIA) method of Schipchandler et al [24], using an IMx ®
Abbot immunoassay instrument (Abbot Laboratories, Illi-
nois, USA). For this method, bound Hcy (oxidized form)BMC Neurology 2008, 8:26 http://www.biomedcentral.com/1471-2377/8/26
Page 3 of 6
(page number not for citation purposes)
is reduced to free Hcy which is then enzymatically con-
verted to S – adenosyl – L – Hcy (SAH). Total free Hcy is
converted to SAH by the use of SAH hydrolase, and excess
adenosine SAH hydrolase converts SAH to Hcy. Excess
adenosine in the pretreatment solution drives the conver-
sion of Hcy to SAH by the bovine SAH hydrolase. A min-
imum volume of 50 ul of plasma is used for the assay.
Mean within-run precision (n = 10) and between-run pre-
cision (n = 10) was 3.8% and 4.5% respectively for the 3
levels of controls used (low, medium and high). Abnor-
mal total Hcy was defined as any level above the 90th per-
centile in the distribution of Hcy in the control
population.
Statistical analysis
Data were analyzed using EPI Info ® 2002 and the Statisti-
cal Package for the Social Sciences (SPSS ®) version 13.0
for Windows®. The Χ2 test was used to compare propor-
tions, whilst the Student t test was used to compare the
mean values of continuous variables between groups.
Multiple linear regression analysis was used to assess the
independent contribution of the variables in the predic-
tion of outcome (GOS score at 4 weeks post stroke). P val-
ues < 0.05 were considered statistically significant.
Results
The study evaluated a total of 155 persons (69 with first-
ever acute ischaemic stroke – 31 women and 38 men; and
86 healthy controls – 35 women and 51 men). The mean
age ± SD of the cases was 58.8 ± 9.8 years, comparable to
that of controls which was 58.3 ± 9.9 years (T = 0.32; P =
0.75). There was no significant difference between the
mean age ± SD of men (58.0 ± 8.9) and women (59.7 ±
11.0) with stroke (T = 0.69; P = 0.49). The clinical and
demographic characteristics specific to the stroke cases,
including admission Glasgow Coma Scale scores, NIHSS
scores, blood pressures (systolic, diastolic and mean arte-
rial pressures), and stroke severity (frequency of mild and
severe stroke) are shown in Table 1.
Homocysteine profile in cases compared to controls
The mean ± SD total fasting Hcy level for acute ischaemic
stroke patients was 10.2 ± 4.6 umol/L. This did not differ
significantly from the level in controls, which was 10.1 ±
3.6 umol/L (P = 0.88). The median Hcy for cases was 9.2
umol/L, while that of controls was 9.6 umol/L. Hyperho-
mocysteinemia was defined by plasma Hcy levels above
the 90th percentile for the control group for each gender.
It was thus defined by plasma Hcy >14.2 umol/L in
women and >14.6 umol/L in men. In all, 7 (10.1%) of the
stroke cases and 11 (12.8%) of the controls had hyperho-
mocysteinemia (odds ratio 0.77, 95% confidence interval
0.27 – 2.12; P = 0.80).
Plasma total Hcy in relation to stroke-specific 
characteristics and outcome
The relationship between plasma total Hcy levels and var-
ious subgroup characteristics was explored. Specifically,
comparisons were made by gender, number of identified
modifiable risk factors (multiple or single), presence of
hypertension, diabetes mellitus, smoking status, and
stroke severity on admission (Table 2).
The case fatality rate in this study was 7.2% (5/69). The
degree of disability at 4 weeks post stroke in the survivors
(n = 64) using the Glasgow Outcome scale as the outcome
measure was as follows: Good recovery – 22 (31.9%),
Moderate disability – 17 (24.6%), Severe disability – 23
(33.3%), and Vegetative – 2 (2.9%). Mean ± SD and
median GOS scores at 4 weeks in cases with normal and
Table 1: Demographic and clinical characteristics of stroke cases and controls
Parameter Cases Controls
n = 69 n = 86 P value
Male to female ratio 38:31 35:51 0.11
Age (years), mean ± SD 58.8 ± 9.8 58.3 ± 9.9 >0.05
Duration of stroke prior to hospitalization (hours), mean ± SD 43.5 ± 38.8 N/A
Hypertension, n (%) 59 (85.5%) 0 (0%) <0.00001
Diabetes mellitus, n (%) 19 (27.5%) 0 (0%) <0.00001
Alcohol consumption, n (%) 22 (31.9%) 19 (22.1%) 0.23
Cigarette smoking, n (%) 5 (7.2%) 2 (2.3%) 0.24
Admission Glasgow coma scale score, mean ± SD 13.8 ± 2.7 N/A
Admission NIHSS score, mean ± SD 10.1 ± 7.7 N/A
Admission systolic blood pressure (mmHg), mean ± SD 160.6 ± 29.1 116.4 ± 29.1 <0.00001
Admission diastolic blood pressure (mmHg), mean ± SD 99.0 ± 17.9 76.9 ± 4.9 <0.00001
Admission mean arterial pressure (mmHg), mean ± SD 119.1 ± 20.8 90.0 ± 5.5 <0.00001
Stroke severity
Mild (NIHSS ≤ 13) 53 (76.8%)
Severe (NIHSS >13) 16 (23.2%) N/A
Blood pressure values for controls represent measurements at time of recruitmentBMC Neurology 2008, 8:26 http://www.biomedcentral.com/1471-2377/8/26
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elevated Hcy were 2.21 ± 1.07 (median = 2.0) and 3.00 ±
1.73 (median = 3.0) respectively (T = 1.73, P = 0.09).
Furthermore, using multiple linear regression analysis, we
explored the possibility of a relationship between GOS
score at 4 weeks (as the dependent variable) and age,
admission systolic BP (SBP), diastolic BP (DBP), mean
arterial pressure (MAP), admission GCS score, admission
NIHSS score, and plasma Hcy as explanatory variables
(Table 3). Using this model, the only variable that was sig-
nificantly associated with GOS score at 4 weeks was the
admission NIHSS score (P < 0.0001). Plasma Hcy level on
admission was not a determinant of short term outcome
as measured by the GOS score (P = 0.07).
Discussion
This study was designed to prospectively explore two
aspects of the relationship between fasting total plasma
Hcy and acute ischaemic stroke in Nigerians. In the first
instance, we sought to compare the prevalence of elevated
Hcy in stroke cases compared to matched controls. Sec-
ondly, we prospectively evaluated the relationship
between Hcy levels (measured within 72 hours of stroke
onset) and short-term outcome in acute ischaemic stroke
in Nigerians using a case-control design.
Our principal findings based on the case-control study are
that the levels of plasma Hcy in cases and their age-
matched controls from the same population were not sig-
nificantly different, and the prevalence of hyperhomo-
cysteinemia was similar in cases and controls. The data
regarding concentrations of Hcy in stroke patients have
been confounding. Lindgren et al compared plasma Hcy
levels in the acute and convalescent periods following
stroke, and found that, in contrast to several earlier stud-
ies, the concentration of plasma Hcy did not differ
between cases and controls in the acute phase, and plasma
Hcy levels were in fact higher in the convalescent period
following stroke [25]. This finding was corroborated in a
more recent study which concluded that decreased Hcy
levels found on admission for acute ischaemic stroke may
reflect the strength of the acute-phase response rather than
Table 2: Comparison of mean plasma total Hcy (umol/L) values based on various intra-group characteristics of stroke cases overall and 
by gender stratification
Variable Total Statistics * Male Female 
N = 69 N(Mean ± SD) N (Mean ± SD) T P
Number of risk factors
Single (n = 40) 10.3 ± 4.5 T = 0.18; P = 0.88 22 (10.0 ± 3.4) 18 (10.6 ± 5.6) 0.42 0.68
Multiple (n = 29) 10.1 ± 4.7 16 (10.7 ± 5.5) 13 (9.3 ± 3.7) 0.79 0.43
Hypertension
Yes (n = 59) 10.1 ± 4.0 T = 0.14; P = 0.89 34 (10.7 ± 4.5) 25 (9.4 ± 3.1) 1.17 0.25
No (n = 10) 10.4 ± 7.6 4 (7.1 ± 1.4) 6 (12.5 ± 9.4) 1.10 0.29
Diabetes
Yes (n = 19) 8.7 ± 3.3 T = 1.71; P = 0.09 6 (8.2 ± 3.1) 13 (8.9 ± 3.4) 0.44 0.66
No (n = 50) 10.7 ± 4.9 32 (10.7 ± 4.5) 18 (10.9 ± 5.6) 0.12 0.90
Smoking
Yes (n = 5) 8.7 ± 3.4 T = 0.74; P = 0.46 5 (10.3 ± 4.7) 0 - -
No (n = 64) 10.3 ± 4.7 33 (10.5 ± 4.5) 31 (10.0 ± 4.9) 0.41 0.68
Admission stroke severity
Mild (NIHSS ≤ 13) (n = 53) 10.2 ± 4.9 T = 0.12; P = 0.91 32 (10.4 ± 4.4) 21 (10.0 ± 5.6) 0.29 0.78
Severe (NIHSS > 13) (n = 16) 10.1 ± 3.5 6 (9.9 4.5) 10 (10.2 3.1) 0.18 0.86
* Comparing the categories e.g. single v. multiple risk factors, hypertension present or absent, diabetes present or absent, smoking yes or no, and 
stroke severity mild or severe
Table 3: Multiple linear regression analysis of determinants of stroke outcome (GOS scores) at 4 weeks post stroke
Variable Coefficient Standard error P value 95% confidence interval
Age -0.004 0.011 0.72 -0.03 0.17
Admission SBP 0.015 0.016 0.37 -0.02 0.04
Admission DBP 0.022 0.035 0.53 -0.05 0.09
Admission MAP -0.023 0.047 0.63 -0.11 0.08
Admission GCS score -0.063 0.054 0.25 -0.16 0.06
Admission NIHSS score 0.087 0.018 <0.0001* 0.05 0.12
Plasma homocysteine 0.041 0.023 0.07 -0.01 0.08
Dependent variable for the model is GOS score at 4 weeks. *GOS scores at 4 weeks were only significantly related to admission NIHSS scores.BMC Neurology 2008, 8:26 http://www.biomedcentral.com/1471-2377/8/26
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a pathogenetic event [26]. Glew et al also evaluated Hcy
levels in ischaemic stroke occurring in Northern Nigeria
and found similar levels in cases and controls [27]. These
findings are supported by the study of Sacco et al who
investigated the association between various degrees of
elevation of Hcy and the risk of incident ischaemic stroke
in a triethnic cohort which included blacks [28]. They
showed that mild to moderate elevations of total Hcy are
less predictive, the vascular effects are less, and total Hcy
is not a significant risk factor for ischaemic stroke among
blacks. Although results of studies exploring the relation-
ship between Hcy and ischaemic stroke have been con-
flicting, several other studies have reported a lack of risk of
stroke attributable to hyperhomocysteinemia and have in
fact on occasion shown a decline in Hcy levels in the acute
post stroke period possibly representing an acute phase
response [25,26,29]. It has been suggested that following
an acute inflammatory reaction, serum albumin concen-
trations decline, and albumin being the principal plasma
Hcy-binding protein, this situation may result in lowering
of total plasma Hcy levels. Spence [30] has however
enjoined caution in interpreting the mechanism underly-
ing lowered Hcy levels in the immediate post-stroke
period, and emphasizes the potential role of recumbency
in reducing the blood levels of several analytes including
Hcy. Furthermore, the Hcy-stroke association may be spe-
cific to certain pathophysiologic subtypes of stroke (such
as large artery atherosclerosis), and may be masked in
studies such as ours in which the vascular subtypes of
ischemic stroke were not separately analyzed [15,31].
Our study also found that elevated Hcy levels were not
related to the occurrence of more severe stroke. Con-
versely, our study results showed a weak association
between severe stroke (measured by admission NIHSS
scores) and lower Hcy levels. Lower Hcy levels in the acute
phase of stroke may in fact represent a more severe acute
phase reaction corresponding to a worse vascular insult.
Perini et al also reported a lack of correlation between ele-
vated plasma Hcy on admission and stroke severity [31].
In the prospective follow-up study, we found that admis-
sion hyperhomocysteinemia was not a determinant of
short-term outcome (measured by the Glasgow outcome
scale score at 4 weeks) following acute ischaemic stroke in
our patients. The relationship between Hcy and stroke
outcome remains controversial, with some studies finding
an association where others have not [32,33]. If hyperho-
mocysteinemia occurs as an effect or epiphenomenon
rather than a cause of acute ischaemic stroke as has been
suggested [34], this may explain why elevated Hcy,
despite not determining stroke severity at the onset, may
have an effect on stroke outcome in the short term, in the
same way that factors such as infections and other compli-
cations acquired in the post-acute phase can impact nega-
tively on short-term outcome.
One of the limitations of our study is that, as is the case
for studies of this nature, the pre-stroke Hcy levels of our
stroke cases were not known, and so we cannot categori-
cally determine if the Hcy levels measured represent a
decline, an increase, or are reflective of pre-stroke values.
An ideal study designed to address this would necessarily
incorporate a cohort with pre-determined Hcy levels (e.g.
at study entry), and followed up on the long-term, pro-
spectively documenting incident strokes and eventually
determining the relationship between Hcy and incident
stroke, while controlling for confounders. Also, our study
conclusions cannot be extrapolated to describe the rela-
tionship between Hcy and stroke outcome on the long
term. We did not explore the relationship between the
vascular subtype (e.g. small vessel versus large vessel dis-
ease) and total plasma Hcy levels, and cannot thus con-
clude on whether elevated Hcy has varying effects based
on the specific vascular subtype of stroke. We also note
that although blood pressure has previously been docu-
mented as an independent determinant of Hcy levels [35],
and though the blood pressure measurements (systolic,
diastolic, and mean arterial pressures) in our cases were
significantly higher than controls, their Hcy levels were
essentially similar. We acknowledge the limitations inher-
ent in the study sample size and thus describe our study as
exploratory, with the intention that further studies
employing a larger sample size can be conducted in the
future.
Conclusion
This exploratory study found that homocysteine levels are
not significantly elevated in Nigerians with acute ischae-
mic stroke, and admission Hcy level is not a determinant
of short-term (4 week) stroke outcome.
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